Intratumoral heterogeneity in gastric cancer: a new challenge to face
- 27 March 2017
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (5) , 912-913
Abstract
Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-death worldwide [1], with an overall survival for advanced disease of ∼1 year. Although classically considered as a single disease, GC is highly heterogeneous from the morphological and molecular standpoints. Noteworthy, GC heterogeneity encompasses not only inter-patient variability (intertumoral heterogeneity) but also variations within the same tumor (intratumoral heterogeneity). The latter includes spatial heterogeneity in different tumor areas, and temporal heterogeneity, along progression from primary to recurrent and/or metastatic disease [2]. Despite this feature, for therapeutic purposes, GC patients have been treated with identical chemo and/or radiotherapy regimens and targeted therapies [3, 4], except for the HER2 positive population [5]....Keywords
This publication has 23 references indexed in Scilit:
- Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatmentAnnals of Oncology, 2016
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical TrialCancer Discovery, 2016
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III TrialJournal of Clinical Oncology, 2016
- Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancerBMC Gastroenterology, 2015
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III StudyJournal of Clinical Oncology, 2014
- The causes and consequences of genetic heterogeneity in cancer evolutionNature, 2013
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancerEuropean Journal of Cancer, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNew England Journal of Medicine, 2008